Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Acts on LPA containing saturated or unsaturated fatty acids C15:0-C20:4 at the sn-1 position using C18:1-CoA as the acyl donor. Also acts on lysophosphatidylethanolamine using oleoyl-CoA, but not arachidonoyl-CoA, and lysophosphatidylinositol using arachidonoyl-CoA, but not oleoyl-CoA. Activity toward lysophosphatidylglycerol not detectable.
IHC of paraffin-embedded Carcinoma of Human bladder tissue using anti-AGPAT5 mouse monoclonal antibody.
IHC of paraffin-embedded Carcinoma of Human prostate tissue using anti-AGPAT5 mouse monoclonal antibody.
IHC of paraffin-embedded Human pancreas tissue using anti-AGPAT5 mouse monoclonal antibody.
IHC of paraffin-embedded Adenocarcinoma of Human endometrium tissue using anti-AGPAT5 mouse monoclonal antibody.
IHC of paraffin-embedded Human Kidney tissue using anti-AGPAT5 mouse monoclonal antibody.
Anti-AGPAT5 mouse monoclonal antibody immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY AGPAT5.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY AGPAT5 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-AGPAT5.
Requested From: United States
Date Requested: 12/7/2016